אלפו-קל XL ישראל - עברית - Ministry of Health

אלפו-קל xl

padagis israel agencies ltd, israel - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason.

רייאטאז 200 מג ישראל - עברית - Ministry of Health

רייאטאז 200 מג

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

נבלבין 20 מג ישראל - עברית - Ministry of Health

נבלבין 20 מג

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

ביקאלוטמיד אינובמד 150 מג ישראל - עברית - Ministry of Health

ביקאלוטמיד אינובמד 150 מג

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

ארומזין ישראל - עברית - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

פייקומפה 2 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 2 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 2 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 4 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 4 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 4 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 6 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 6 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 6 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 8 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 8 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 8 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

פייקומפה 10 מג טבליות מצופות ישראל - עברית - Ministry of Health

פייקומפה 10 מג טבליות מצופות

eisai israel ltd., israel - perampanel as anhydrous - טבליות מצופות פילם - perampanel as anhydrous 10 mg - perampanel - perampanel - fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.